Table 1.
Patient characteristics
| Age [median years (IQR)] | 60 (21) | |
| Gender [n (%)] | Males | 43 (53.8) |
| Females | 37 (46.3) | |
| Stage [n (%)] | Stage 0 | 4 (5) |
| Stage IA | 12 (15) | |
| Stage IB | 12 (15) | |
| Stage IIA | 11 (13.8) | |
| Stage IIB | 10 (12.5) | |
| Stage IIC | 9 (11.3) | |
| Stage IIIA | 1 (1.3) | |
| Stage IIIB | 4 (5) | |
| Stage IIIC | 14 (17.5) | |
| Stage IIID | 1 (1.3) | |
| Unknown | 2 (2.5) | |
| Nodal involvement [n (%)] | Yes | 19 (23.8) |
| No | 49 (61.3) | |
| Unknown | 12 (15) | |
| Ulceration [n (%)] | Yes | 34 (42.5) |
| No | 46 (57.5) | |
| Breslow thickness [median mm (IQR)] | 2.2 (3) | |
| Pathology [n (%)] | Malignant melanoma (NOS) | 11 (13.8) |
| In situ | 4 (5) | |
| Lentigo maligna | 3 (3.8) | |
| Acrolentigionous | 6 (7.5) | |
| Nodular melanoma | 23 (28.7) | |
| Superficial spreading | 23 (28.7) | |
| Other types | 9 (11.3) | |
| Unknown | 1 (1.3) | |
| Tissue BRAF [n (%)] | Mutated | 23 (28.7) |
| Wild type | 29 (36.3) | |
| Unavailable | 28 (35) | |
| Relapse [n (%)] | Yes | 19 (23.8) |
| No | 61 (76.3) | |
| Vital status [n (%)] | Alive | 72 (90) |
| Dead | 8 (10) | |
IQR, interquartile range; NOS, not otherwise specified.